Navigation Links
ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
Date:6/10/2008

anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.


'/>"/>
SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Prometic provides information for its Annual and Special Meeting of Shareholders
2. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
3. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
4. Prometic to present at the American Chemical Society
5. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
6. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
7. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
8. ProMetic provides business update - Over $35 million worth of business secured in January
9. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
10. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
11. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... California (PRWEB) July 28, 2014 The ... 604.40 billion by 2020, according to a new study ... with the rising demand for effective vaccines and drugs ... with unmet medical needs is expected to drive market ... need to enhance agricultural productivity via the use of ...
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Analysis Market 2014-2018" report to their offering. ... analysis is a technique used to determine the size of ... It is crucial to analyze the size of particles as ... size analysis is performed to determine the behavior and nature ...
(Date:7/25/2014)... 2014 "Ischemic Stroke and Cerebral ... data on the Ischemic Stroke and Cerebral Stroke ... and data relating to the clinical trials on ... global Ischemic Stroke Research Report 2014 at: ... the trial numbers and their recruitment status as ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3
... to be Held Wednesday, May 7, 2008 at 10:00 ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) will host a ... ended March 31, 2008 on,Wednesday, May 7, 2008 at ... conference call can be accessed through the,company,s website at: ...
... scientists first learned to make nanowires, the nano-sized wires ... taken many forms, including nanobelts, nanocoils and nanoflowers. , ... and graduate student Matthew Bierman accidentally made some pine ... and branches that tapered in length as they spiraled ...
... HER3 Assays to Provide Unique Insights and ... Cancer Therapies, SOUTH SAN FRANCISCO, May 1 ... the company,s HER1,and HER3 Quantitative Protein Assays are now ... the HER1 and,HER3 assays provide unique, quantitative measurements of ...
Cached Biology Technology:Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results 2Spiraling nanotrees offer new twist on growth of nanowires 2Spiraling nanotrees offer new twist on growth of nanowires 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5
(Date:7/28/2014)... the Earth that are high priorities for conservation in ... vulnerable, as it has the lowest fraction of its ... in ,refugia, areas of biological diversity that support ... during times of great environmental change. The refugia that ... Scotland. , The biggest refugia are in the ...
(Date:7/28/2014)... CITY (July 28, 2014)The Brain & Behavior Research ... Klerman and Freedman Prizes, recognizing exceptional clinical and ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research for the prevention, ... that affect one in four people. , Six ...
(Date:7/28/2014)... suffer from fertility problems, many of these due to ... might expect such genes, which reduce an individual,s ability ... the Weizmann Institute of Science that recently appeared in ... riddle. Not only can it explain the high rates ... in understanding the causes of genetic diseases and their ...
Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Mutations from Venus, mutations from Mars 2
... S-equol, a novel soy germ-based compound, is very likely ... dietary supplement SE5-OH, which is under development for reduction ... studies using an animal model presented at the Experimental ... advanced studies in menopausal women, and peer-reviewed reports have ...
... MIAMI - As Florida Governor Charlie Crist declared a ... scientists at the Center for Southeastern Tropical Advanced Remote ... actively collaborate with several international satellite data providers to ... The Deepwater Horizon oil platform caught fire after an ...
... first personalized treatment for lung cancer heralds the arrival ... will demand significant changes to the way cancer specialists ... today at the 2nd European Lung Cancer Conference in ... University of Vienna said that personalized therapy, in which ...
Cached Biology News:Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 2Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 3Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 4Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 5Making personalized lung cancer therapy a reality in Europe 2
...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
...
Biology Products: